How to buy Veracyte stock (VCYT)

Veracyte is a diagnostics & research business based in the US. Veracyte shares (VCYT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $40.89 – a decrease of 5.39% over the previous week. Veracyte employs 815 staff and has a trailing 12-month revenue of around $425.3 million.

Our top picks for where to buy Veracyte stock

Buy Veracyte stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Veracyte stock price (NASDAQ: VCYT)

Use our graph to track the performance of VCYT stocks over time.

Veracyte shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$40.89
52-week range	$18.61 - $46.00
50-day moving average more info button	$37.89
200-day moving average more info button	$27.90
Wall St. target price	$43.22
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.13

Is it a good time to buy Veracyte stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Veracyte price performance over time

Historical closes compared with the close of $40.89 from 2024-12-20

1 week (2024-12-13)	-5.39%
1 month (2024-11-22)	3.28%
3 months (2024-09-20)	17.40%
6 months (2024-06-21)	81.41%

1 year (2023-12-22)	44.64%
2 years (2022-12-22)	54.48%
3 years (2021-12-22)	43.62
5 years (2019-12-20)	43.37%

Is Veracyte stock undervalued or overvalued?

Valuing Veracyte stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Veracyte's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Veracyte's EBITDA

Veracyte's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $44 million.

The EBITDA is a measure of a Veracyte's overall financial performance and is widely used to measure a its profitability.

Veracyte financials

Revenue TTM	$425.3 million
Operating margin TTM	10.53%
Gross profit TTM	$195 million
Return on assets TTM	1.07%
Return on equity TTM	-0.83%
Profit margin	-2.18%
Book value	$15.18
Market Capitalization more info button	$3.1 billion

TTM: trailing 12 months

Veracyte share dividends

We're not expecting Veracyte to pay a dividend over the next 12 months.

Veracyte share price volatility

Over the last 12 months, Veracyte's shares have ranged in value from as little as $18.61 up to $46. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 1.668. This would suggest that Veracyte's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Veracyte overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.

Frequently asked questions

What percentage of Veracyte is owned by insiders or institutions?
Currently 0.785% of Veracyte shares are held by insiders and 104.382% by institutions. How many people work for Veracyte?
Latest data suggests 815 work at Veracyte. When does the fiscal year end for Veracyte?
Veracyte's fiscal year ends in December. Where is Veracyte based?
Veracyte's address is: 6000 Shoreline Court, South San Francisco, CA, United States, 94080 What is Veracyte's ISIN number?
Veracyte's international securities identification number is: US92337F1075 What is Veracyte's CUSIP number?
Veracyte's Committee on Uniform Securities Identification Procedures number is: 92337F107